RhoVac AB is present at the Investival Showcase in London and Sedermeradagen in Stockholm

RhoVac AB ("RhoVac") further expands its international presence by presenting the company at investment and partnering conferences in Europe in November. RhoVac will present at the Investival Showcase in London and at Sedermeradagen in Stockholm. For details about the events, see the information below.

RhoVac's business strategy is, and has been since the founding of the company, to outsource or sell all or part of the business after the ongoing clinical phase I/II study has been completed. Attending international conferences such as London Investival Showcase and Jefferies is, according to the Board of Directors of the company, to maximize the potential of this strategy. At the Nordic Life Science Days conference, where RhoVac participated in September this year, great interest was shown for the company's cancer vaccine project. RhoVac held successful meetings with a number of international pharmaceutical companies that showed interest in knowing more about the project. RhoVac is now following up on the meetings with the contacts made at this conference.

RhoVac will be attending the Investival Showcase on November 14, 2017, arranged in collaboration with Jefferies Investment Bank, and is presenting the company in the Immuno-Oncology section at the conference. More than 200 global investors will attend in the Investival Showcase, where 70 companies will present. At the London conference, where RhoVac will participate with two representatives, we will present the company on stage. In addition, the company intends to hold individual meetings with potential partners and investors. For more information about the Investival Showcase, see http://www.biotechandmoney.com/investival-showcase. RhoVac is also attending Jefferies Global Healthcare Conference, the largest healthcare conference in Europe, where 350 companies with 1,400 participants will participate.

In order to further strengthen the relationship with investors in Scandinavia, RhoVac will present at Sedermeradagen Stockholm November 16th, 2017. At Sedermeradagen Stockholm, the company's CEO Anders Ljungqvist will present the status of RhoVac's development project and the company's plans for 2017/2018. Sedermeradagen will be held at the Waterfront Congress Center in Stockholm. For registration and more information about Sedermeradagen, see http://www.sedermeradagen.se/stockholm-16-november-2017/.

For more information, please contact:

Anders Ljungqvist – VD, RhoVac AB

Phone: +45 4083 2365

E-mail: alj@rhovac.com

About RhoVac AB

RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com


Documents & Links